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Abstract 1 
Ultrasound-mediated targeted drug delivery (UmTDD) is a therapeutic modality under 2 
development, with potential to treat cancer. Its ability to produce local hyperthermia and cell 3 
poration through cavitation non-invasively makes it a candidate to trigger drug delivery. 4 
Hyperthermia offers greater potential for control, particularly with magnetic resonance imaging 5 
(MRI) temperature measurement. However, cavitation may offer reduced treatment times, with real-6 
time measurement of ultrasonic spectra indicating drug dose and treatment success. Here, a clinical 7 
MRI-guided focused ultrasound surgery (MRgFUS) system was used to study UmTDD in vitro. 8 
Drug uptake into breast cancer cells in the vicinity of ultrasound contrast agent was correlated with 9 
occurrence and quantity of stable and inertial cavitation, classified according to sub-harmonic 10 
spectra. During stable cavitation, intracellular drug uptake increased by a factor up to 3.2 compared 11 
to the control. This paper demonstrates the value of cavitation monitoring with a clinical system, 12 
and its subsequent employment for dose optimisation.  13 
 14 
Keywords: Targeted Drug Delivery, Focused Ultrasound, Microbubbles, Cancer cell, Cavitation, 15 
Subharmonic, Ultrasound contrast agent. 16 
  17 
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Introduction 18 
Hyperthermia and cavitation are the ultrasound-related mechanisms that have been reported to 19 
cause increased intracellular drug uptake (Böhmer et al. 2009; Liu et al. 2001; Wu and Nyborg 20 
2008; Gourevich et al. 2013). The term ‘cavitation’ describes two different physical processes, 21 
stable and inertial, with the latter sometimes termed ‘transient’ cavitation, that affect cells in 22 
different ways. Whilst evidence exists that both types of cavitation can be utilised in ultrasound-23 
mediated targeted drug delivery (UmTDD) (Sundaram et al. 2003; Schlicher et al. 2006; Karshafian 24 
et al. 2009), the literature provides conflicting information on which method may yield the most 25 
effective results under a given set of experimental conditions (Fan et al. 2013; Domenici et al. 26 
2013).  27 
Stable and inertial cavitation have been shown to have different acoustic signatures, based on their 28 
differing underlying physics and the mechanical index (MI) of the ultrasound from which they 29 
originate (Leighton 1997; Brennen 1995). During stable cavitation, the bubbles oscillate, changing 30 
size and sometimes shape. These oscillations are associated with the phenomenon of 31 
microstreaming (Wu and Nyborg 2008) and can be detected by characteristic scattering of the 32 
applied ultrasound. In the frequency domain, the detected ultrasound depends on the type of 33 
oscillation (de Jong et al. 2009) and consists of harmonics, subharmonics and ultra-harmonics of the 34 
fundamental driving ultrasound frequency. The scattered acoustic signal acquired during 35 
sonoporation occurring as a result of inertial cavitation (Frenkel 2008) also has a characteristic 36 
signature in the frequency domain, in this case broadband. Passive detection of scattered acoustic 37 
emissions acquired during therapeutic ultrasound has been used to predict efficacy thresholds for 38 
ablation (Jensen et al. 2013), and explored as a means to investigate exploitable conditions for 39 
sonoporation (Fan et al. 2014; Somaglino et al. 2011; Chen et al. 2003; Hallow et al. 2006) e.g. by 40 
using the sub-harmonic spectrum amplitude as an indication of sonoporation occurrence (Hensel et 41 
al. 2009). Thus further insight into the mechanisms responsible for biological effects related to 42 
UmTDD can be gained through defining and correlating the types of cavitation generated with 43 
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transfection and cell viability results (Bazan-Peregrino et al 2012; Gao et al, 2008; Fan 2031; 44 
Hassan 2010).  45 
An additional major concern regarding UmTDD in vitro is the ability to differentiate cavitation 46 
effects from those correlated with increased temperature and verification that any heating produced 47 
unavoidably does not contribute to the observed biological effects. In this context, in the work 48 
presented here the experimental environment was based on a clinical magnetic resonance imaging 49 
guided focused ultrasound surgery (MRgFUS) system which allowed differentiation between the 50 
heating and cavitation mechanisms associated with ultrasound application. This system was 51 
characterized to gain understanding of the physical properties affecting the outcomes of cell culture 52 
experiments, and hence aid in overcoming difficulties in reproducibility of results in in vitro 53 
UmTDD experiments as has been raised previously by different authors (ter Haar et al. 2011; 54 
Hassan et al. 2010; Hensel et al. 2011; Kinoshita 2007; Leskinen and Hynynen, 2012). 55 
Following arduous and lengthy experimental work in vitro and in vivo (Chen et al. 2010), 56 
therapeutic ultrasound is becoming an established clinical modality used mainly for tissue ablation, 57 
hyperthermia, and lithotripsy (Crouzet al. 2010; Lafon et al. 2002; ter Haar 1995; Barnett et al. 58 
1994; Jolesz 2009). However, notwithstanding the work of others (Bazan-Peregrino et al 2012; 59 
Razavi et al. 2014), cavitation-based UmTDD is not yet sufficiently developed for clinical 60 
application and development is still under way, as required for tumour treatment, of techniques to 61 
monitor cavitation and to determine how cavitation may be used to predict resultant drug dose. This 62 
paper aims to contribute new knowledge on optimized values and conditions relating to use of 63 
cavitation in UmTDD to assist in development of this important therapeutic modality. 64 
Materials and Methods 65 
Experimental Apparatus and Setup 66 
An ExAblate 2000 system (InSightec, Tirat Carmel, Israel) was used as the sonication platform in 67 
the described in vitro study. The source of ultrasound in this system is a concave phased array with 68 
26 annuli each divided into eight sectors to give a total of 208 transmitting ultrasonic array elements 69 
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organised in 26 transducer rings (Tr), The radius of curvature is 160 mm, aperture 120 mm, and the 70 
operating frequencies can be set in the range of 0.95 - 1.35 MHz. Quasi-continuous excitation is 71 
used, making the bandwidth extremely small for any given frequency. The array elements can be 72 
turned on and off individually and also allow phase adjustment with 45° quantisation. An additional 73 
complete concave element with radius 11.5 mm acts as a receiver, located coaxially with the 74 
transmitting array to allow spectral responses to be recorded. Signals are acquired from the 75 
receiving element for 150 ms every 200 ms, using a low-pass filter with a cut-off frequency of 76 
approximately 700 kHz to reduce the amplitude of the transmitted signal. After each acquisition, the 77 
signal is subjected to a fast Fourier transform (FFT) and the frequency domain result is recorded.  78 
The ExAblate 2000 system complies with international HITU standards - IEC62555 (HITU 79 
radiation force) and IEC62556 (HITU field characterization) as well as IEC60601 (“Medical 80 
electrical equipment:  Particular requirements for the basic safety and essential performance of high 81 
intensity therapeutic ultrasound (HITU) equipment”), and is calibrated accordingly. In addition, it 82 
was tested prior to each set of sonications, using the same method as for its clinical application, i.e. 83 
by sonication of a specially manufactured daily quality assurance (DQA) phantom which verified 84 
the dimensions of the focal zone as well as its delivery to a specified location. 85 
Ninety six-well polystyrene µ-clear plates with a 0.2 mm thick base (Greiner Bio-One, Stonehouse, 86 
UK) were found to be the best cell culture environment, with manageable heat effects and space to 87 
fit the focal spot within the 7 mm diameter and 10 mm depth of each well. Titer-Tops sealing film 88 
(EMS, Hatfield, PA, USA) with a thickness of 0.1 mm was used to seal the open tops of the wells to 89 
maintain the sterility of the cells’ microenvironment and to reduce acoustic boundary interface 90 
effects by allowing complete plate immersion in water. 91 
To ensure that the wells did not behave as ultrasonic waveguides during sonication (Sommer et al. 92 
1997, Redwood 1960), which would shift focal point toward the distal end of the well, we reduced 93 
the focal zone diameter which excited different propagation modes, allowing ultrasound 94 
propagation in the well not as a plane wave but with some interference between the modes (Figure 95 
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1A). This indicated there is a trade-off between the spot size and waveguide effects when sonicating 96 
an inverted 96-well plate using focused ultrasound.  97 
In order to validate the optimal parameters for sonication inside a well, acoustic field measurements 98 
were performed as described below. The full experimental setup is depicted in Figure 1B and Figure 99 
1C shows the order in which the wells were sonicated. To reduce secondary effects caused by 100 
accumulated dissipation of acoustic power in neighbouring wells, the sonicated wells were 101 
separated by wells with various contents (e.g. with microbubbles (MBs), without MBs and empty). 102 
The sonication order was also set in such a way as to avoid sonicating two neighbouring wells one 103 
after another and to minimize time-related effects on MBs by sonicating wells containing MBs first, 104 
as shown in Figure 1C. The 96-well plate was placed 92 mm above the transducer. 105 
Acoustic and Thermal Evaluation  106 
To estimate acoustic power loss and unwanted heat distribution, a separate base portion of a 96-well 107 
plate, supplied by the manufacturer, and the Titer-Tops sealing film were mounted in a special 108 
frame and scanned acoustically. To determine how much of the acoustic power was dissipated 109 
during the sonication, we utilised externally gated, pulsed sonications, each only a few seconds 110 
long, using the ExAblate transducer as the ultrasound source. A 0.5 mm polyvinylidene difluoride 111 
(PVDF) needle hydrophone (Precision Acoustics, Dorchester, UK) was placed in the focal plane of 112 
the transducer to record the waves. Acoustic scanning equipment described previously (Gourevich 113 
et al. 2013) was used to scan a 2D plane and the amplitude of the ultrasonic wave-front through a 114 
focal plane was recorded in water and with the base and sealing parts of the 96-well plate immersed 115 
between the transducer and the hydrophone.  116 
The relatively small well diameter of 96-well plates means that care must be taken when they are 117 
used in ultrasound-related in vitro experiments. To determine suitability, detect possible limitations, 118 
and identify an appropriate sonication pattern, i.e. the focal distance (FD) and the form of the beam, 119 
two sets of experiments were done. First, successively increasing proportions (20%, 50% then 120 
100%) of the array elements from the centre outwards were activated coherently to narrow the focal 121 
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width increasingly, while leaving the remaining elements inactive. Second, increasing proportions 122 
(0%, 50% then 100%) of the array elements were excited with random phases to determine the 123 
effect of coherence. As detailed in the Results, the most appropriate activation of those investigated 124 
was determined to be of the central 50% of the array elements (13 annuli) with coherent excitation. 125 
An additional issue that may influence the focal behaviour is the FD inside a well. Because of the 126 
plate geometry, as stated above, various disruptions can occur during the passage of the beam 127 
through the well. To establish the optimal height for sonication inside a single well within a plate, 128 
which will yield minimal distribution of power to the neighbouring wells, and to evaluate the 129 
influence of a sonication on neighbouring wells, acoustic field measurements were performed over 130 
an inverted plate at different focal points. The hydrophone in these measurements was less than 1 131 
mm from the surface of the inverted plate, bringing it into close proximity with the theoretical cell 132 
location. 133 
To differentiate between the thermal and mechanical effects that are associated with application of 134 
ultrasound, thermal measurements were made with an infrared (IR) thermal imaging camera (FLIR 135 
Systems CeDIP JADE camera, Kent, UK). A 96-well plate was only partly immersed in water, to 136 
overcome the opacity of water to IR wavelengths. The plate was sonicated at room temperature 137 
(RT) using different acoustic power levels for 90 s each, allowing cooling time between the 138 
sonications. 139 
Cavitation Spectrum Measurements 140 
The definition of cavitation dose, CD, used here is based on an approach in which, for each time 141 
acquisition, the magnitude of the signal in the frequency domain is integrated around the 142 
subharmonic frequency, f = 0.475 ±0.1 MHz, and these values are further integrated for the whole 143 
period of the sonication, as defined in Equation 1 (Hallow et al. 2006). 144 
                                                       𝐶𝐷 =  ∑ ∫ 𝑎(𝑓)𝑑𝑓0.5750.375 𝑡                                                       (1) 145 
This definition allows a distinction between experiments in which there is no cavitation and those 146 
with stable and inertial cavitation, where lower values of CD indicate no cavitation and larger 147 
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values indicate stable and then inertial cavitation. The fundamental unit of CD in this scheme is 148 
mV. 149 
Figure 2 shows three examples of possible cavitation spectrum readings, as recorded by the 150 
ExAblate 2000 during ultrasonic exposure of cells within treatment groups containing MB, (A) 151 
showing no cavitation; (B) showing a single subharmonic peak from non-linear stable cavitation; 152 
and (C) showing broadband noise from inertial cavitation. Linear cavitation was not studied during 153 
this research. 154 
Cell Maintenance 155 
Cultures of MCF-7 human breast cancer cells (American Type Culture Collection (ATCC), 156 
Manassas, Virginia, USA) were grown as monolayers on 75 cm2 cell culture flasks (TPP Techno 157 
Plastic Products AG, Trasadingen, Switzerland) in Complete Medium (CM) i.e. Dulbecco’s 158 
Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% 159 
penicillin streptomycin (5000 I.U./ml, 5000 lg/ml; Gibco Invitrogen, Paisley, UK). They were kept 160 
in humidified air with 5% CO2 at 37ºC. Re-seeding of the cells was performed twice each week 161 
using Trypsin-ethylenediaminetetraacetic acid (EDTA) 0.05% (Gibco Invitrogen, Paisley, UK). 162 
For UmTDD studies, 15,000 cells/well were seeded in 100 µL CM, in µ-clear 96-well plates 163 
(Greiner Bio-One, Stonehouse, UK) three days in advance, in order to reach confluence on the day 164 
of the experiment. Prior to the application of ultrasound, the CM in the wells was replaced with the 165 
following solutions: 166 
• Uptake studies - Treatment group: 25 µM doxorubicin (Dox) (Discovery, Wimborne, UK)  in 167 
CM with 0.025% dimethyl sulfoxide (DMSO) and 4.7% of ultrasound contrast agent (USCA) 168 
Sonovue solution, i.e. 4 x 106  MBs per well (Bracco Research SA, Milan, Italy); Control: 169 
Dox in CM with 0.025% DMSO.   170 
• Viability assessment - Treatment group: CM with MB at the same concentration, i.e. 4 x 106 171 
MBs per well; Control: CM only. 172 
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• Membrane Permeability assessment - Treatment group: CM with MB at the same 173 
concentration, i.e. 4 x 106 MBs per well; Control: CM only. 174 
In all the experiments, the Sonovue MBs were prepared according to the manufacturer’s 175 
instructions and kept in an ice bath throughout the experiment, except when in use. The MBs were 176 
added to the final Dox/CM solution in individual portions per plate and the final solutions were 177 
applied immediately to the cell monolayers. 178 
The uptake of Dox into the MCF-7 cell line was investigated using fluorescence intensity 179 
measurement (Infinite M200, Tecan Group, Mannedorf, Germany) with excitation and emission 180 
wavelengths of 485 nm and 592 nm, respectively. Following ultrasound treatment, it was observed 181 
that some cells detached from the mono-layer. This detachment was attributed to ultrasound 182 
application and extensive cell washing to remove excess Dox left between the cells. As the detached 183 
cells were discarded during the washes, they did not contribute to the total fluorescence reading. 184 
Therefore we correlated the uptake, as indicated by the fluorescence measurements, with the 185 
number of viable cells. This was achieved by normalization of the fluorescence readings by the total 186 
protein amount present within each well after ultrasound exposure, using the bicinchoninic acid 187 
(BCA) assay (Smith et al. 1985). The recorded protein amounts following sonication were also 188 
compared to the control groups to estimate the level of cell loss due to the different treatments. 189 
The viability of cells after ultrasound exposure was quantified by MTT (3-(4,5-Dimethylthiazol-2-190 
yl)-2,5-diphenyltetrazolium bromide; Sigma-Aldrich, Dorset, UK), a colorimetric assay which 191 
correlates with cells’ viability via their enzymatic activity (Cole 1986; Twentyman and Luscombe 192 
1987). Additionally, a membrane integrity test (CytoTox-ONE, Promega, UK) was conducted to 193 
quantify the level of membrane permeability due to ultrasound application (Cho et al. 2002). In the 194 
presence of MBs, ultrasound is known to increase cell membrane permeability. Therefore, 195 
measurement of lactate dehydrogenase (LDH) levels released from leaking membrane into the 196 
media can indicate the level of membrane permeability achieved by sonication. The level of 197 
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resofurin, which is proportional to the amount of LDH, was measured by fluorescence intensity 198 
measurements (Kaur et al 2007). 199 
Experimental Procedure and Ultrasound Application 200 
The solutions described above were added to each well, to a total volume of 420 µL, according to 201 
the defined treatment groups (Figure 1C) and the plates were sealed using Titer-Tops (EMS, 202 
Hatfield, PA, USA). The cells were sonicated continuously for 10 s with the following parameters; 203 
acoustic power level, P = 1 W, as the defined output of the ExAblate 2000 system which was 204 
focused at the centre of each well in all axes (FD = 97 mm); peak negative pressure, PNP = 205 
0.53 MPa; intensity, I = 18.77 W/cm2; mechanical index, MI = 0.54; and frequency, f = 0.95 MHz. 206 
The plate was placed inverted to ensure that the MBs were in proximity to the cell monolayer, 207 
owing to MB buoyancy. The sonications were performed in the order shown in Figure 1C, such that 208 
the wells containing the MBs were sonicated first. 209 
Following the sonication process, the cells were washed twice with phosphate-buffered saline (PBS; 210 
Oxoid, Basingstoke, UK). For the uptake studies, the cells were lysed with 0.5% sodium dodecyl 211 
sulphate (SDS; Sigma-Aldrich, Dorset, UK) and the total fluorescence intensity of each well was 212 
recorded and normalized by total protein count using the BCA method (Smith et al. 1985). The 213 
cellular uptake of the sonicated samples was calculated as a percentage of the unsonicated samples, 214 
i.e. the control group, which was seeded in the same 96-well plate: 215 
𝐷𝑟𝑢𝑔 𝑈𝑝𝑡𝑎𝑘𝑒 = � 𝐷𝑜𝑥 𝐹𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 [𝑅𝐹𝑈]𝑠𝑎𝑚𝑝𝑙𝑒𝑇𝑜𝑡𝑎𝑙 𝑃𝑟𝑜𝑡𝑒𝑖𝑛 𝐴𝑚𝑜𝑢𝑛𝑡 [𝜇𝑔]𝑠𝑎𝑚𝑝𝑙𝑒� � 𝐷𝑜𝑥 𝐹𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 [𝑅𝐹𝑈]𝑐𝑜𝑛𝑡𝑟𝑜𝑙
𝑇𝑜𝑡𝑎𝑙 𝑃𝑟𝑜𝑡𝑒𝑖𝑛 𝐴𝑚𝑜𝑢𝑛𝑡 [𝜇𝑔]𝑐𝑜𝑛𝑡𝑟𝑜𝑙�         (2) 216 
The cell loss in each well after sonication was established according to the BCA absorbance 217 
readings relative to the control group, by: 218 
𝐶𝑒𝑙𝑙 𝐿𝑜𝑠𝑠 = �𝑇𝑜𝑡𝑎𝑙 𝑃𝑟𝑜𝑡𝑒𝑖𝑛 𝐴𝑚𝑜𝑢𝑛𝑡 [𝜇𝑔]𝑠𝑎𝑚𝑝𝑙𝑒
𝑇𝑜𝑡𝑎𝑙 𝑃𝑟𝑜𝑡𝑒𝑖𝑛 𝐴𝑚𝑜𝑢𝑛𝑡 [𝜇𝑔]𝑐𝑜𝑛𝑡𝑟𝑜𝑙�         (3) 219 
The viability studies were performed to determine if the sonication on its own, with and without 220 
MBs, caused cell necrosis, regardless of the presence of Dox. For assessment of cell viability, the 221 
same procedure was performed as in the uptake studies, where the indicated solutions were added to 222 
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the different groups and the cells were sonicated at the specified parameters. Following the 223 
sonication process, 100 µL of fresh CM was added after two washes with PBS, then the cell 224 
viability was either assessed immediately or cell recovery studies were performed. The latter 225 
included additional 24 h incubation at 37 ºC in 5% CO2. The cell viability was assessed by addition 226 
of 20 µL of MTT and 3 h incubation at 37 ºC in 5% CO2. The created formazan was dissolved in 227 
100 µL DMSO (Gibco Invitrogen, Paisley, UK), the plate was shaken for 50 s and the absorption 228 
signal at 550 nm was recorded with a plate reader (Infinite M200, Tecan Group Mannedorf, 229 
Germany). The level of cell viability was calculated relative to the control group of unsonicated 230 
cells: 231 
𝐶𝑒𝑙𝑙 𝑉𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 = �𝑀𝑇𝑇 𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒𝑠𝑎𝑚𝑝𝑙𝑒−𝐵𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑
𝑀𝑇𝑇 𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒𝑐𝑜𝑛𝑡𝑟𝑜𝑙−𝐵𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑�  (4) 232 
In the membrane permeability studies, the plate was centrifuged at 2000 rpm for 10 min to spin 233 
down any cells present in the medium following sonication. 50 µL of the medium in each well were 234 
transferred into a new black 96-well plate (Greiner Bio-One, Stonehouse, UK) and an equivalent 235 
amount of resazurin reagent was added. After an incubation period of 10 min at RT, the stop 236 
solution was added and the fluorescent signal was measured with an excitation wavelength of 237 
560 nm and emission wavelength of 590 nm. The fluorescence readings were normalized by the 238 
total protein amount using the BCA method as described above. The membrane permeability was 239 
calculated as follows: 240 
𝑀𝑒𝑚𝑏𝑟𝑎𝑛𝑒 𝑃𝑒𝑟𝑚𝑒𝑎𝑏𝑖𝑙𝑖𝑡𝑦 = � 𝐿𝐷𝐻 [𝑅𝐹𝑈]𝑠𝑎𝑚𝑝𝑙𝑒−𝐵𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑𝑇𝑜𝑡𝑎𝑙 𝑃𝑟𝑜𝑡𝑒𝑖𝑛 𝐴𝑚𝑜𝑢𝑛𝑡 [𝜇𝑔]𝑠𝑎𝑚𝑝𝑙𝑒� � 𝐿𝐷𝐻 [𝑅𝐹𝑈]𝑐𝑜𝑛𝑡𝑟𝑜𝑙−𝐵𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑
𝑇𝑜𝑡𝑎𝑙 𝑃𝑟𝑜𝑡𝑒𝑖𝑛 𝐴𝑚𝑜𝑢𝑛𝑡 [𝜇𝑔]𝑐𝑜𝑛𝑡𝑟𝑜𝑙�               (5) 241 
All the ultrasound cell culture studies were performed in a water environment at 30ºC, the upper 242 
temperature limit of the experimental setup.  243 
For each plate, nine replicates were done for each treatment group and an additional six replicates 244 
for each type of control group. Throughout the various uptake, viability and membrane permeability 245 
experiments, each set of applied ultrasound parameters was replicated at least three times to ensure 246 
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statistically significant data collection and correlation with spectral recording. All the values in the 247 
results section are presented with their standard deviations. 248 
Results 249 
Characterisation of Setup 250 
In our experimental set up we found that the base of the µ-clear 96-well plate and the Titer-Tops 251 
sealing caused minimal attenuation of the acoustic signals, with, on average, 95.7% and 99.8% of 252 
the transmitted power passed through the base and the sealing, respectively (Figure 3A). Figure 3B 253 
represents the acoustic measurements at different focal points performed at 50% Tr with an acoustic 254 
power of 1 W at 0.95 MHz. The acoustic field measurements above the 96-well plate, showed that I 255 
in neighbouring wells is less than 4% of the peak intensity of the targeted well, with the minimal I 256 
distribution to the neighbouring wells being when the focus is in the middle of the well, i.e. 257 
FD = 97 mm. The acoustic field measurements showed that changing the aperture of the transducer 258 
by deactivating outer elements increased the focal length and diameter as expected, as well as 259 
distorting the focal shape, especially at 20% Tr (Figure 3C). Based on these measurements, the 260 
aperture of the transducer to be applied was established as using half the transmitting elements 261 
(50% Tr) and chosen such that the focal zone diameter entering the well was 2.6 mm.  262 
According to the results of the thermal camera measurements presented in Figure 4 for the chosen 263 
ultrasound parameters, with P = 1 W for 10 s, the overall temperature rise was only 0.44°C 264 
(±0.2°C). 265 
Biological Studies and Cavitation Spectrum Measurement 266 
Analysis of the relationship between the cell results and the cavitation spectrum measurements was 267 
applied to two groups. The first group, represented by Figure 5, contains all the measurement points 268 
from all the intracellular drug uptake and membrane permeability experiments. The second group, 269 
represented by Table 1 and Figures 6 and 7, contains results averaged ±SD in accordance with the 270 
sonication order, i.e. time of sonication, presented in Figure 2B. 271 
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Figure 5A shows the dependence of intracellular drug uptake on the CD. There is a distinct 272 
separation in outcome depending on the presence or absence of MBs. Without MBs, no significant 273 
cavitation occurs, as is also evident in the uptake levels which are below a factor of 1.5 relative to 274 
the control group. On the contrary, with MBs, the drug uptake varies by factors from 1.5 up to 3.2 275 
with varying CD. Figure 5B depicts the correlation between the permeability of the cells’ 276 
membranes as a result of ultrasound application.  277 
As can be seen in Figure 5B, there is a significant increase in the membrane permeability of the 278 
cells, by a factor up to 3.5, in the presence of MBs, with an increasing trend with decreasing CD 279 
values. Figure 5C shows the dependence of drug uptake on the cell loss, where a linear fitting 280 
represents the relation between the uptake values and the number of cells missing from each well 281 
after sonication and washing. According to this trend, higher levels of cell loss correspond to higher 282 
uptake values, which can be explained by the fact that larger effects on the cell membrane cause 283 
greater penetration of the cytotoxic drug into the cells. This is also evident from the linear 284 
correlation between the uptake and the cell membrane permeability (Figure 5D). 285 
Table 1 differentiates between stable and inertial cavitation for the different wells containing MB, 286 
according to the order of sonication. The classification in Table 1 was performed according to the 287 
maximum CD spectrum reading for each sonication; thus, if the sonication is classified as stable, it 288 
is assumed that no inertial cavitation has taken place. From Table 1, it can be seen that the 289 
occurrence of inertial cavitation decreases over time, corresponding to the order of sonication, 290 
whilst stable cavitation occurs instead. Our results show that the recorded CD = 0.22 ± 0.06mV and 291 
higher correspond to the occurrence of inertial cavitation, whereas CD = 0.15 ± 0.02 mV and lower 292 
correlate with stable cavitation. 293 
Figure 6 presents the dependence of the drug uptake, membrane permeability and CD on the time 294 
passing after the first sonication. As previously mentioned, the treatment groups without MB were 295 
sonicated last. It can be seen that sonications without the MBs produce consistent results both for 296 
the intracellular drug uptake and membrane permeability, with up to 20% variation from the 297 
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average value: these results are not time dependent. On the other hand, sonications performed on 298 
the wells with MBs manifest a bigger span of results and are time-dependent. 299 
The dependence of immediate viability and cell recovery studies on the order of the sonications is 300 
presented in Figure 7A and B, respectively. The trend-lines shown in Figures 6 and 7 are the linear 301 
fitting representations of the dependence of the groups containing MBs on the order of sonication. 302 
Discussion 303 
This study was designed to define the individual contributions of stable and inertial cavitation to 304 
intracellular uptake of a chemotherapic agent within cancer cells. The initial step was the 305 
characterisation of the experimental arrangements including 96-well plates sonicated with a 306 
clinically approved system. This has confirmed that the use of the standard cell culture environment 307 
does not compromise the properties of the ultrasound propagation. Moreover, the acoustic energy 308 
levels that were used do not cause significant thermal effects, allowing differentiation between 309 
hyperthermia and cavitation.   310 
Our Dox uptake results indicate a threshold between drug uptake and cavitation activity with and 311 
without MBs. While there was no effect on either the uptake or the membrane permeability in the 312 
absence of MBs, the intracellular drug uptake was, on average, increased by a factor of 2.14 ± 0.46 313 
relative to the control group in the presence of MBs.  314 
Membrane integrity tests were conducted to gain better understanding of the mechanism of uptake 315 
enhancement by MBs in acoustic environment. The membrane integrity assay quantified the level 316 
of LDH present in the media due to leaking cell membranes. Accordingly, it was possible to 317 
evaluate the membrane permeability achieved by sonication. In this study we utilised a simple 318 
fluorescence-based measurement technique to validate the mechanism of drug uptake into the cells. 319 
The close correlation between the increases in cellular uptake and the membrane permeability (i.e. 320 
3.2 and 3.5 fold, respectively) indicate that membrane permeability studies involving quantification 321 
of LDH levels can be used as a tool to establish the levels of membrane permeability caused by the 322 
application of ultrasound. 323 
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The average decrease in viability of cells immediately after sonication in the wells containing MBs 324 
was recorded as 31% ± 8% relative to the control group. Taken together with the 24 h recovery 325 
studies, where the average decrease in the same group was 19% ± 5%, this indicates that some of 326 
the cell damage caused by sonication was reversible and did not lead directly to cell death. 327 
Therefore we conclude that there is an acoustic intensity window inside which the permeability of 328 
the cell membranes increases due to the presence of ultrasound-driven MBs which allows greater 329 
intracellular drug uptake, while permeabilisation is not permanent as it does not cause excessively 330 
high levels of cell death. 331 
The drug uptake dependence on cell loss along with the cell viability studies indicated that greater 332 
cell loss is caused by the increased uptake of toxic drugs into the cells, rather than for any other 333 
reason. The average results of the cell culture studies are in agreement with previously described 334 
work by other authors using different experimental configurations (Pitt et al. 2004). 335 
The dependence of drug uptake on CD indicates that greater uptake is achieved for smaller values 336 
of CD, i.e. 0.12 mV < CD < 0.19 mV, suggesting that stable, non-linear cavitation with a peak at ½ 337 
the transmitting frequency is responsible for greater uptake and membrane permeability. Indeed, 338 
sorting the results according to the order of the sonicated wells, we have found that inertial 339 
cavitation occurred mainly within the first four sonicated wells, whereas stable cavitation was 340 
detected mainly in the last three sonicated wells that contained MBs. From the representation of the 341 
results as a function of time starting at the first sonication, there is a trend of increased drug uptake 342 
and reduced CD. This suggests that the increased drug uptake into the cell monolayers in our 343 
experiments was caused by stable, rather than inertial, cavitation. The dependence of the uptake on 344 
cell loss shows that stable cavitation also caused a greater cell loss. This is also evident in the 345 
immediate viability studies where there is a reduction in viability as a function of time similar to the 346 
CD. Nonetheless, this trend is decreased in the 24 h recovery studies as shown by the fact that the 347 
slope of the linear trend in the 24 h viability is half that generated from immediate viability studies. 348 
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We have calculated that the initial MB concentration was enough to cover the surface of the cells in 349 
a single monolayer, yet not high enough to attenuate the ultrasound beam. Therefore, we 350 
hypothesize that the initial inertial cavitation in our experiments, during the first three sonications, 351 
was caused by destruction of MBs in their original form, being unstable due to their relatively large 352 
diameters (e.g. > 9 µm). As, initially, the fraction of MBs in this range of diameters is significantly 353 
smaller than for other diameters (Gorce et al. 2000), the impact of the inertial cavitation on cell loss, 354 
viability and drug uptake is lower. After 100 s, the time between the first and the seventh 355 
sonications, larger quantities of the MBs retained diameters of 8 - 9 µm due to their spontaneous 356 
increase in diameter in a time dependent manner at temperature above RT (Guiot et al. 2006; 357 
Mulvana et al. 2010, 2011; Vos et al. 2008). These MBs are more attuned to resonate at 358 
f = 0.95 MHz (Gorce et al. 2000), the ultrasonic frequency in use, and hence a greater effect was 359 
achieved due to the irregular oscillations associated with stable non-linear cavitation. 360 
Conclusions 361 
In this study, a clinically approved MRgFUS system was used for cell studies in vitro. Adaptation 362 
of a clinical system in this way carries the potential for use of a single system from in vitro studies 363 
through the pre-clinical stage to clinical trials. Moreover, a well-defined experimental setup that can 364 
be used in a clinical environment promotes a reproducible baseline of in vitro and in vivo results, 365 
which can promote related research, e.g. in conjugation with novel drug carriers (Wang and 366 
Thanoua 2010), in multiple centres. The ability offered by this system to quantify cavitation dose 367 
has the potential to explain previously obscure results. The method used for cavitation detection in 368 
this study has advantages of robustness and simplicity. More precise cavitation detection methods 369 
have been suggested by Gyongy and Coussios, 2010. The use of the passive cavitation detection 370 
method they describe, along with the method described in our work, will allow better localization of 371 
cavitation and correlation between the sub-harmonics and harmonics and the intracellular drug 372 
uptake. 373 
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The absolute values of the drug uptake results presented here are in line with previously reported 374 
work by other authors using different experimental configurations. Moreover, the spectral recording 375 
that has been performed has allowed us to determine that the highest drug uptake was achieved in 376 
the presence of stable, non-linear cavitation. According to our findings, there is higher uptake at 377 
lower CD values. This is contradictory to the common assumption that UmTDD is governed by 378 
inertial cavitation (Somaglino et al. 2011; Razavi et al. 2014). Here we have provided evidence that 379 
stable cavitation with a lower CD, in the presence of MB, produces a greater impact on the 380 
intracellular uptake. This should be taken into account in future cavitation related TDD studies. 381 
Moreover, the hypothesis driven from our studies with Sonovue MB suggests that the time for 382 
ultrasound application to the MB is crucial and should be carefully controlled and reported in the 383 
literature. 384 
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List of Tables 518 
Table 1- Distribution of the stable and inertial cavitation during the uptake studies, between the ten 519 
repetitions in each well with MBs in the plate. For example out of ten repetitions of the third 520 
sonication, inertial cavitation occurred nine times and stable cavitation once. The order of the 521 
sonications in the plate is shown in Figure 1C. 522 
 523 
Sonication Order 1 2 3 4 5 6 7 8 9 
Time (s) 10 28 44 60 76 92 110 126 142 
Inertial Cavitation 9 8 9 9 4 5 1 2 1 
Stable Cavitation 1 2 1 2 6 5 9 8 9 
 524 
